Amicus Therapeutics, Inc.: Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected ...
CMU and Healthcare System Secures Unprecedented 17 Awards at the 2024 Taiwan National Innovation Awards
The Taiwan National Innovation Awards, regarded as the pinnacle of excellence in the biomedical and healthcare sectors, ...
Outset Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN JOSE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first ...
Hansa Biopharma AB: Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare ...
Outset Medical Announces Private Placement Financing and New Debt Agreement
Outset Medical, Inc. (NASDAQ: OM) revealed, in an 8-K form filed on January 3, 2025, several significant financial transactions. The company entered into securities purchase agreements for the ...